Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents

Seokmin Kang, Jung Moo Lee, Borami Jeon, Ahmed Elkamhawy, Sora Paik, Jinpyo Hong, Soo Jin Oh, Sun Ha Paek, Changjoon Lee, Ahmed H.E. Hassan, Sang Soo Kang, Eun Joo Roh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested. However, trifluoperazine did not increase the survival time in mice models of glioblastoma. In attempt to identify an effective trifluoperazine analog, fourteen compounds have been synthesized and biologically in vitro and in vivo assessed. Using MTT assay, compounds 3dc and 3dd elicited 4–5 times more potent inhibitory activity than trifluoperazine with IC50 = 2.3 and 2.2 μM against U87MG glioblastoma cells, as well as, IC50 = 2.2 and 2.1 μM against GBL28 human glioblastoma patient derived primary cells, respectively. Furthermore, they have shown a reasonable selectivity for glioblastoma cells over NSC normal neural cell. In vivo evaluation of analog 3dc confirmed its advantageous effect on reduction of tumor size and increasing the survival time in brain xenograft mouse model of glioblastoma. Molecular modeling simulation provided a reasonable explanation for the observed variation in the capability of the synthesized analogs to increase the intracellular Ca2+ levels. In summary, this study presents compound 3dc as a proposed new tool for the adjuvant chemotherapy of glioblastoma.

Original languageEnglish
Pages (from-to)186-198
Number of pages13
JournalEuropean Journal of Medicinal Chemistry
Volume151
DOIs
Publication statusPublished - 2018 May 10

Fingerprint

Trifluoperazine
Glioblastoma
Computer Simulation
Antipsychotic Agents
Tumors
Brain
Molecular modeling
Chemotherapy
Inhibitory Concentration 50
Heterografts
Assays
Survival
Adjuvant Chemotherapy
Brain Neoplasms

Keywords

  • Brain cancer
  • Calcium
  • Glioblastoma
  • Orthotopic brain xenograft mouse model
  • Trifluoperazine
  • Trifluoperazine analogs

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Repositioning of the antipsychotic trifluoperazine : Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. / Kang, Seokmin; Lee, Jung Moo; Jeon, Borami; Elkamhawy, Ahmed; Paik, Sora; Hong, Jinpyo; Oh, Soo Jin; Paek, Sun Ha; Lee, Changjoon; Hassan, Ahmed H.E.; Kang, Sang Soo; Roh, Eun Joo.

In: European Journal of Medicinal Chemistry, Vol. 151, 10.05.2018, p. 186-198.

Research output: Contribution to journalArticle

Kang, Seokmin ; Lee, Jung Moo ; Jeon, Borami ; Elkamhawy, Ahmed ; Paik, Sora ; Hong, Jinpyo ; Oh, Soo Jin ; Paek, Sun Ha ; Lee, Changjoon ; Hassan, Ahmed H.E. ; Kang, Sang Soo ; Roh, Eun Joo. / Repositioning of the antipsychotic trifluoperazine : Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. In: European Journal of Medicinal Chemistry. 2018 ; Vol. 151. pp. 186-198.
@article{d8aaa416844e4379a0d05139da02df6f,
title = "Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents",
abstract = "Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested. However, trifluoperazine did not increase the survival time in mice models of glioblastoma. In attempt to identify an effective trifluoperazine analog, fourteen compounds have been synthesized and biologically in vitro and in vivo assessed. Using MTT assay, compounds 3dc and 3dd elicited 4–5 times more potent inhibitory activity than trifluoperazine with IC50 = 2.3 and 2.2 μM against U87MG glioblastoma cells, as well as, IC50 = 2.2 and 2.1 μM against GBL28 human glioblastoma patient derived primary cells, respectively. Furthermore, they have shown a reasonable selectivity for glioblastoma cells over NSC normal neural cell. In vivo evaluation of analog 3dc confirmed its advantageous effect on reduction of tumor size and increasing the survival time in brain xenograft mouse model of glioblastoma. Molecular modeling simulation provided a reasonable explanation for the observed variation in the capability of the synthesized analogs to increase the intracellular Ca2+ levels. In summary, this study presents compound 3dc as a proposed new tool for the adjuvant chemotherapy of glioblastoma.",
keywords = "Brain cancer, Calcium, Glioblastoma, Orthotopic brain xenograft mouse model, Trifluoperazine, Trifluoperazine analogs",
author = "Seokmin Kang and Lee, {Jung Moo} and Borami Jeon and Ahmed Elkamhawy and Sora Paik and Jinpyo Hong and Oh, {Soo Jin} and Paek, {Sun Ha} and Changjoon Lee and Hassan, {Ahmed H.E.} and Kang, {Sang Soo} and Roh, {Eun Joo}",
year = "2018",
month = "5",
day = "10",
doi = "10.1016/j.ejmech.2018.03.055",
language = "English",
volume = "151",
pages = "186--198",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Repositioning of the antipsychotic trifluoperazine

T2 - Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents

AU - Kang, Seokmin

AU - Lee, Jung Moo

AU - Jeon, Borami

AU - Elkamhawy, Ahmed

AU - Paik, Sora

AU - Hong, Jinpyo

AU - Oh, Soo Jin

AU - Paek, Sun Ha

AU - Lee, Changjoon

AU - Hassan, Ahmed H.E.

AU - Kang, Sang Soo

AU - Roh, Eun Joo

PY - 2018/5/10

Y1 - 2018/5/10

N2 - Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested. However, trifluoperazine did not increase the survival time in mice models of glioblastoma. In attempt to identify an effective trifluoperazine analog, fourteen compounds have been synthesized and biologically in vitro and in vivo assessed. Using MTT assay, compounds 3dc and 3dd elicited 4–5 times more potent inhibitory activity than trifluoperazine with IC50 = 2.3 and 2.2 μM against U87MG glioblastoma cells, as well as, IC50 = 2.2 and 2.1 μM against GBL28 human glioblastoma patient derived primary cells, respectively. Furthermore, they have shown a reasonable selectivity for glioblastoma cells over NSC normal neural cell. In vivo evaluation of analog 3dc confirmed its advantageous effect on reduction of tumor size and increasing the survival time in brain xenograft mouse model of glioblastoma. Molecular modeling simulation provided a reasonable explanation for the observed variation in the capability of the synthesized analogs to increase the intracellular Ca2+ levels. In summary, this study presents compound 3dc as a proposed new tool for the adjuvant chemotherapy of glioblastoma.

AB - Repositioning of the antipsychotic drug trifluoperazine for treatment of glioblastoma, an aggressive brain tumor, has been previously suggested. However, trifluoperazine did not increase the survival time in mice models of glioblastoma. In attempt to identify an effective trifluoperazine analog, fourteen compounds have been synthesized and biologically in vitro and in vivo assessed. Using MTT assay, compounds 3dc and 3dd elicited 4–5 times more potent inhibitory activity than trifluoperazine with IC50 = 2.3 and 2.2 μM against U87MG glioblastoma cells, as well as, IC50 = 2.2 and 2.1 μM against GBL28 human glioblastoma patient derived primary cells, respectively. Furthermore, they have shown a reasonable selectivity for glioblastoma cells over NSC normal neural cell. In vivo evaluation of analog 3dc confirmed its advantageous effect on reduction of tumor size and increasing the survival time in brain xenograft mouse model of glioblastoma. Molecular modeling simulation provided a reasonable explanation for the observed variation in the capability of the synthesized analogs to increase the intracellular Ca2+ levels. In summary, this study presents compound 3dc as a proposed new tool for the adjuvant chemotherapy of glioblastoma.

KW - Brain cancer

KW - Calcium

KW - Glioblastoma

KW - Orthotopic brain xenograft mouse model

KW - Trifluoperazine

KW - Trifluoperazine analogs

UR - http://www.scopus.com/inward/record.url?scp=85044581432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044581432&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.03.055

DO - 10.1016/j.ejmech.2018.03.055

M3 - Article

C2 - 29614416

AN - SCOPUS:85044581432

VL - 151

SP - 186

EP - 198

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -